KEYNOTE-867

Non-Small Cell Lung Cancer

• Has previously untreated non-small cell lung cancer (NSCLC) diagnosed by histology or cytology and confirmed as Stage I or II (T1 to limited T3, N0, M0) NSCLC (American Joint Committee on Cancer, AJCC) by chest computed tomography (CT) and positron emission tomography (PET) scan. Participants with pericardium invasion, >2 nodules or 2 nodules that cannot be treated in one field (>2 cm apart and/or total planned target volume [PTV] >163 cc) and diaphragm elevation suggestive of phrenic nerve invasion are excluded
• Cannot undergo thoracic surgery due to existing medical illness(es) as determined by the site's multi-disciplinary tumor board. Medically operable participants who decide to treat with stereotactic body radiotherapy (SBRT) as definitive therapy rather than surgery are also eligible, if patient's unwillingness to undergo surgical resection is clearly documented
• Has a Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
• Is able to receive SBRT and does not have an ultra-centrally located tumor
• Has adequate organ function within 7 days prior to the start of study treatment
• Has a radiation therapy plan approved by the central radiation therapy quality assurance vendor

• The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or II (Stage IIB N0, M0) non-small cell lung cancer (NSCLC).
• The primary study hypotheses are:
  
• SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared to SBRT plus placebo (normal saline solution), and
  
• SBRT plus pembrolizumab prolongs Overall Survival (OS) compared to SBRT plus placebo.
  

Please click here for more information.